Portola chalks up two big pharma names in factor Xa antidote tie-up

Date November 05, 2012

Portola Pharmaceuticals, a US biotech firm that has for years been touted as a flotation candidate, seems instead to have focused on cementing its reputation as a master deal-maker.

Its latest tie-up, covering the blood thinner antidote PRT4445, adds two more companies – Pfizer and Bristol-Myers Squibb – to the list of big pharma names that have been associated with the private biotech group. If it yields positive data this exploratory alliance could give Portola an important boost in an area with no current competition, as well as perhaps leading to a lucrative formal licensing deal.

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd